GEN Exclusives

More »

GEN News Highlights

More »
Sep 20, 2012

Monsanto Applies Therapeutic Platform to Agbiotech

  • Monsanto negotiated an exclusive worldwide license to apply biopharma firm Complix’s Alphabody® platform in the agricultural field. The deal also includes options to expand the collaboration across multiple applications within plant agriculture, and Complix retains exclusive rights to use any discoveries made through the collaboration in nonagricultural fields.

    Alphabodies are small single-chain alpha-helical proteins that Complix claims combine the specificity of antibodies with small molecule-like properties. The proteins are essentially constructed from three associated alpha-helices connected by flexible linker loops to form a single-chain protein. Based on naturally occurring protein scaffolds and modified through computer-aided design, the resulting molecules can be designed against a broad range of disease targets, including intracellular targets.

    Founded in 2008, Belgian firm Complix is leveraging the Alphabody platform to develop therapeutic candidates against autoimmune disorders, infectious diseases, and cancer. The firm says its cell-penetrating Alphabodies (CPAB) can be designed against just about any known intracellular target, including those that are intractable to small molecule drugs or biologics.

    The deal with Monsanto represents the first in which the platform is being applied in agriculture. “Complix’s expertise in protein targeting technology offers a novel platform to further enhance our trait development capabilities,” explains Bob Reiter, vp for biotechnology at Monsanto. “We believe this technology offers great promise and could contribute to development of new traits to protect plants from pests and diseases.”


Readers' Comments

Posted 09/21/2012 by KBN Rayana

Does Alpha bodies restricts the pests and diseases.

It is too early to know this because in Ag. Biotech when we thought of introduceing the Antibiotics on plants which mere sucess. For which we force to found alternative / similar nature available from the soil and applied in HAL(hindustan antibiotics -Govt. of India firm) in 1980`s. Thereafter there is no research conducted since I am not in that firm. Under the circumustances I am very much doubt of this application in practicle. Further any trait will come up may prone to other impacts which is far behind the Agronomic systems (which is required to develop the crop /trait)

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Connectomics Advocacy

How might connectomics maintain lasting support?